Phaseline

Companies › BiOneCure Therapeutics

BiOneCure Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BIO-106
anti-TROP-2 antibody-drug conjugate
TACSTD2Phase 1Advanced CancerApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05320588BIO-106Phase 1Advanced CancerOncologyApr 2027

Targets

TACSTD2 (1)

Companies with the same targets

Sichuan Baili Pharmaceutical Gilead Sciences AstraZeneca Merck & Co. (MSD) Klus Pharma Lepu Biopharma Daiichi Sankyo Roche Sichuan Kelun-Biotech Biopharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.